Eli Lilly’s Olomorasib Study: A Step Forward in Hepatic Impairment Treatment

Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study.

Study Overview: Eli Lilly and Company recently completed a study titled An Open-Label, Nonrandomized, Single-Dose, Safety and Pharmacokinetic Study of LY3537982 in Participants With Hepatic Impairment and Healthy Participants. The primary aim was to evaluate how the drug olomorasib enters the bloodstream and is processed by the body in individuals with varying degrees of liver impairment compared to those with normal liver function. The study also assessed the safety and tolerability of olomorasib.

Intervention/Treatment: The intervention tested was olomorasib, an orally administered drug. It was given to participants with mild, moderate, and severe hepatic impairment as well as to healthy participants, to understand its pharmacokinetics and safety profile.

Study Design: This Phase 1 study was interventional and non-randomized, using a parallel assignment model. It was open-label, meaning no masking was involved, with the primary purpose focused on basic science to understand the drug’s behavior in the body.

Study Timeline: The study began on December 2, 2024, and was last updated on September 19, 2025. These dates are crucial as they indicate the study’s progression and the timeliness of the data, which is important for stakeholders tracking the development of olomorasib.

Market Implications: The completion of this study could positively influence Eli Lilly’s stock performance by demonstrating progress in their drug development pipeline. Investors may view this as a sign of potential future revenue streams, especially if olomorasib proves effective and safe. Competitors in the pharmaceutical industry are likely monitoring these developments closely, as advancements in treatments for hepatic impairment can shift market dynamics.

The study is now completed, with further details available on the ClinicalTrials portal.